Insulet Corp

Health Care
Medical/Dental Instruments
www.insulet.com

Earnings Score
Moat Score
Safety Score

Market Cap $18.14B
PE 43
Debt $1.46B
Cash $953.40M
EV $18.65B
FCF $305.40M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$418.30M
EBIT	$308.90M
ROE	35%
ROA	10%
FCF	$305.40M
Equity	$1.21B
Growth Stability	39%
PE	43.36
PEG	0.38
PB	14.97
P/FCF	59.39
P/S	8.76
Price/Cash	0.05
Debt/Equity	1.21
Debt/FCF	4.79
Net Margins	20%
Gross Margins	70%
Op. Margins	15%
Earnings CAGR	32%
Sales Growth YoY	17%
Sales Growth QoQ	10%
Sales CAGR	24%
FCF CAGR	1%
Equity CAGR	43%
Earnings Stability	0.2
Earnings Growth YoY	-3%
Earnings Growth QoQ	30%

Earnings CAGR 5Y	114%
Sales CAGR 5Y	23%
FCF CAGR 5Y	19%
Equity CAGR 5Y	29%
Earnings CAGR 3Y	26%
Sales CAGR 3Y	26%
FCF CAGR 3Y	399%
Equity CAGR 3Y	51%
Market Cap	$18.14B
Revenue	$2.07B
Assets	$3.09B
Total Debt	$1.46B
Cash	$953.40M
Shares Outstanding	70.07M
EV	18.65B
Earnings Score	12%
Moat Score	94%
Safety Score	56%
Final Score	54%
Working Capital	1.36B
Current Ratio	3.58
Gross Profit	$1.45B
Shares Growth 3y	0%
Equity Growth QoQ	8%
Equity Growth YoY	65%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide.

SEC Filings

Direct access to Insulet Corp (PODD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Insulet Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Insulet Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 32%

Stability 20%

loading chart...

Insulet Corp Discounted Cash Flow

Fully customizable DCF calculator online for Insulet Corp.

Years

Calculation mode

= $3.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$305M	$308M	$311M	$314M	$316M	$319M	$322M	$325M	$328M	$331M	$333M	$3.3B
DCF		$280M	$257M	$236M	$216M	$198M	$182M	$167M	$153M	$140M	$129M	$1.3B
Value	$3.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-28%	-8%	-6%	1%	2%	1%	2%	0%	12%	20%	20%
ROA	-	-2%	-0%	5%	4%	3%	6%	2%	9%	10%	10%
ROE	-	-46%	-17%	2%	15%	1%	3%	1%	28%	35%	35%

Good Net Margins (20.19%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-53.64	-15.72	-4.68	-13.6	-23.89	-7.22	-366.49	20.9	4.79	4.79
Debt over Equity	5.04	5.27	3.57	2.79	11.7	1.78	2.34	3	2	1.21	1.21
Growth Stability	-	-	-	-	-	-	100%	39%	100%	100%	39%

Bad Debt/FCF ratio (4.79)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.21)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (39%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	39%	26%	22%	31%	23%	21%	19%	30%	22%	23%
Earnings YoY growth	-	-61%	-7%	-112%	252%	-41%	147%	-73%	4K%	103%	114%
Equity YoY growth	-	85%	151%	34%	-64%	695%	-8%	-14%	54%	65%	29%
FCF YoY growth	-	-73%	481%	251%	-48%	-31%	300%	-98%	-2K%	336%	19%